Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Guggenheim 

Krystal Biotech diskutieren

Krystal Biotech

WKN: A2JH2F / Symbol: KRYS / Name: Krystal Biotech / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

204,90 €
-0,97 %

Einschätzung Buy
Rendite (%) -31,38 %
Kursziel 199,63
Veränderung
Endet am 11.09.25

Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target raised by analysts at Stifel Nicolaus from $204.00 to $220.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 8,19 %
Kursziel 202,57
Veränderung
Endet am 05.11.25

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 25,47 %
Kursziel 201,99
Veränderung
Endet am 12.12.25

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $212.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 27,27 %
Kursziel 210,55
Veränderung
Endet am 18.12.25

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 34,89 %
Kursziel 202,14
Veränderung
Endet am 18.12.25

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $212.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 21,14 %
Kursziel 212,20
Veränderung
Endet am 19.02.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 18,96 %
Kursziel 208,60
Veränderung
Endet am 20.02.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target raised by analysts at Chardan Capital from $212.00 to $218.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 14,63 %
Kursziel 205,35
Veränderung
Endet am 20.02.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 18,10 %
Kursziel 212,43
Veränderung
Endet am 28.02.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $221.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 23,03 %
Kursziel 228,54
Veränderung
Endet am 05.03.26

Krystal Biotech, Inc. (NASDAQ: KRYS) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $245.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 41,65 %
Kursziel 211,37
Veränderung
Endet am 28.04.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target raised by analysts at HC Wainwright from $221.00 to $240.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 67,27 %
Kursziel 212,50
Veränderung
Endet am 06.05.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $240.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 75,58 %
Kursziel 193,05
Veränderung
Endet am 07.05.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $219.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 69,48 %
Kursziel 166,60
Veränderung
Endet am 07.05.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target lowered by analysts at Guggenheim from $195.00 to $189.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 65,71 %
Kursziel 207,05
Veränderung
Endet am 24.06.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $240.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 58,47 %
Kursziel 164,24
Veränderung
Endet am 22.07.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target lowered by analysts at Bank of America Corporation from $193.00 to $192.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 62,94 %
Kursziel 204,41
Veränderung
Endet am 25.07.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $240.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 62,94 %
Kursziel 186,52
Veränderung
Endet am 25.07.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $219.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 72,47 %
Kursziel 189,46
Veränderung
Endet am 05.08.26

Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $219.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat

Einschätzung Buy
Rendite (%) 61,28 %
Kursziel 186,08
Veränderung
Endet am 22.08.26

Krystal Biotech (NASDAQ:KRYS) had its price target lowered by analysts at Chardan Capital from $219.00 to $216.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat